<?xml version="1.0" encoding="UTF-8"?>
<p id="Par19">Categorisation of risks in the EU-RMP was based on the current definitions as laid down in GVP module V rev 2, i.e. important identified risks, important potential risks, and areas of missing information [
 <xref ref-type="bibr" rid="CR3">3</xref>]. We categorised sources of evidence that formed the bases for the variation to the MA as non-clinical studies, clinical trials, observational studies, and spontaneous reports. We also assessed whether aRMMs were imposed on medicines following EU referral procedures, i.e. (urgent) reviews of the benefitâ€“risk balance of a medicine or class of medicines due to quality, safety, or efficacy issues.
</p>
